| I.1 | Introduction (Preview Free Article) |
| | David R. Holmes, MD; Anthony DeMaria, MD; Nabil Dib, MD, MSc; Spencer King III, MD; David G. Reuter, MD, PhD |
| I.2 | Overview of Cardiovascular Translational Research (Preview Free Article & Lectures From Doctors Dib & Califf) |
| | Nabil Dib, MD, MSc |
| I.3 | A Needs-Based Approach to Health Technology Innovation: The Stanford Biodesign Process Concept Development for Unmet Clinical Needs |
| | Todd J. Brinton, MD; Uday N. Kumar, MD; Jonathan G. Schwartz, MD; Paul G. Yock, MD |
| I.4 | Intellectual Property and Strategy Development |
| | Neil K. Nydegger, Esq |
| I.5 | Business Planning, Product Development and Fundraising: The Three Amigos of Your Device Start-Up |
| | Stanton Rowe |
| I.6 | Regulatory Requirement for Marketing Approval |
| | Felipe Aguel; Deborah G. Castillo, PhD; Joseph Chin, MD; Bram D. Zuckerman, MD |
| I.7 | Regulatory Assessment of Medical Devices in the European Union |
| | Alan G. Fraser, MD; Robert A. Byrne, PhD; Tom Melvin, MD; Niall MacAleenan, MD; Olga Tkachenko, PhD; Paul Piscoi, MD |
| I.8 | Requirements for Reimbursement for Innovation |
| | Joseph Chin, MD; Seth Clancy |
| I.9 | The ABCs of Reimbursement for Breakthrough Devices |
| | Tonya Dowd, MPH; Simran Madhani |
| I.10 | Requirement for New Technology to be Included in the Guidelines: “The Ultimate Goal” |
| | Alice Jacobs, MD |
| I.11 | Advanced Biostatistics for Translational Research |
| | Chris Mullin; Roseann White |
| I.12 | Early Feasibility Studies |
| | Andrew Farb, MD; David G. Reuter, MD, PhD |